Company Overview and News

 
Akzo Nobel India Limited - Shareholders meeting

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Change in Director(s)

2018-09-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India appoints Rajiv Rajgopal as MD

2018-09-07 thehindubusinessline
Paint maker Akzo Nobel India on Friday announced the appointment of Rajiv Rajgopal as its Managing Director from November 1.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Change in Director(s)

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Change in Director(s)

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Cessation

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Shareholders meeting

2018-08-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

1
ONGC, GIC Housing, MOIL, Pfizer results

2018-08-01 thehindubusinessline
Seventy three companies including Akzo Nobel India, Avantel, Capital First, Deepak Nitrite, GE Power, GIC Housing Finance, Godrej Properties, Ibulls Housing Fin, International Paper, JK Lakshmi Cement, Mahindra Logistics, Mahindra Holidays, Manpasand, Majesco, Marico, MOIL, ONGC, Pfizer, Ramco Cements, Rane Holdings, Raunaq EPC, Transport Corporation, Torrent Pharma and Uttam Sugar will declare their quarterly results for the April-June period on Thursday
GICHSGFIN BAJAJ-AUTO 500710 532938 533150 RMCTY INPAP CAPF 532977 511676 DEEPAKNI 500380 500260 GODREJPROP IP RANEHOLDIN RAMCOCEM AKZOINDIA JKLAKSHMI 505800 506401

 
Akzo Nobel India Limited - Post Buyback Public Announcement

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Post Buyback Public Announcement

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Akzo Nobel India Limited - Updates

2018-07-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500710 AKZOINDIA

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 freepressjournal.in
New Delhi: Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER HINDUNILVR 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 500696 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 thehindubusinessline
Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

4
Akzo Nobel India: Buyback offer opens

2018-07-05 thehindubusinessline
The buyback offer of Akzo Nobel India will open for subscription by its shareholders on Friday and close on July 19. The company intends to buy back 11.20 lakh shares at a price of ₹2,100 a share, with the total buyback size adding up to ₹235.20 crore.
500710 AKZOINDIA 500570 TATAMOTORS TTM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...